A review of gadolinium-based contrast agents in the setting of repeated MRI for high risk breast cancer screening. Review uri icon

Overview

abstract

  • Women who are considered high risk for breast cancer are recommended to undergo supplemental breast cancer screening annually with MRI. There are primarily three safety concerns associated with gadolinium-based contrast agents which include allergic reactions, nephrogenic systemic fibrosis and gadolinium deposition. In this review, we discuss how these risks are affected by molecular structure, will specifically review the difference between the two commonly used agents, gadobutrol and gadoterate, and discuss the most recent FDA approved contrast agent on the market, gadopiclenol.

publication date

  • February 3, 2025

Research

keywords

  • Breast Neoplasms
  • Contrast Media
  • Gadolinium
  • Magnetic Resonance Imaging

Identity

Digital Object Identifier (DOI)

  • 10.1016/j.clinimag.2025.110420

PubMed ID

  • 39938355

Additional Document Info

volume

  • 120